Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
© The REDOXS Study REducing Deaths due to OXidative Stress The REDOXS© Study REducing Deaths from OXidative Stress Study Chair Dr. Daren Heyland, MD, FRCPC ials G i d a a l C ar e ro t ic Tr a n Cri Project Leader Rupinder Dhaliwal, BASc, RD up C an Research Questions In critically ill patients with severe organ dysfunction, what is the effect of: 1) Glutamine supplementation compared to placebo on 28-day mortality? 2) Antioxidant supplementation compared to placebo on 28-day mortality? Effect of Glutamine: A Systematic Review of the Literature Mortality www.criticalcarenutrition.com Effect of Glutamine: A Systematic Review of the Literature Infectious Complications www.criticalcarenutrition.com Effect of Combined Antioxidant Strategies in the Critically Ill Effect on Mortality Inferences Glutamine/day Antioxidants per day Parenterally Enterally 0.35 gms/kg 30 gms 500 mcg Selenium Vit C 1500 mg Vit E 500 mg B carotene 10 mg Zinc 20 mg Se 300 ug • High dose appears safe • High dose associated with – – – – no worsening of SOFA Scores greater resolution of oxidative stress greater preservation of glutathione Improved mitochondrial function Heyland JPEN Mar 2007 Design antioxidants Factorial 2x2 design 1200 ICU patients Evidence of organ failure glutamine R R placebo antioxidants placebo R placebo Study Groups GLN +AOX Enteral Supplement Parenteral Supplement Glutamine + AOX Dipeptiven + Selenium Placebo + Selenium Dipeptiven + Placebo Placebo + Placebo AOX AOX only GLN Glutamine only Placebo SC blinded Placebo Pharmacist unblinded © REDOXS Teamwork Site Investigator Pharmacist Regulatory Inclusion/exclusion criteria ICU infection adjudication SAE reporting Checking allocation Dispensing Logs Dietitian Study Coordinator Regulatory Screening/Randomization Pharmacy communication Data collection Supplement monitoring Collaboration with SI SAE reporting Protocol Violation reporting Optimizing nutrition Monitoring Adequacy Optimizing Enteral Nutrition Canadian CPGs www.criticalcarenutrition.com Feeding Protocol Elevate the Head of the Bed Motility Agents Small Bowel Feeding Baseline Nutrition Dietitian to collect: • Prescribed kcal and protein (baseline) • Type of nutrition support • Start and stop date and times • Refer to Dietitian Manual Dietitian Checklist Study Supplement Compliance • Volumes must be monitored DAILY in real time. • If volumes < prescribed, need to report to CERU or provide explanation and take action to prevent recurrence. Protocol Violation Protocol Deviation Administration of Study Supplements Enteral Study Supplement EN REDOXS © Formula Parenteral Study Supplements (Dipeptiven and Selenium) + Start of Supplements • Start ASAP – within 24 hrs of admission to ICU – within 2 hrs of randomization • Duration: 28 days or death or discharge – min of 5 days • Parenteral supplements – – – – as soon as patient resuscitated 10 ml/hr dedicated central port (eg. one of a triple lumen) can run peripherally if needed (watch for phlebitis) Do NOT infuse with medications; IV fluids, albumin, nutrition OK • Enteral supplement – NG tube OK or feeding tube – 20 ml/hr, can be given via Y connector – start regardless of whether docs want to start enteral nutrition • Maximize EN nutrient and nutrition delivery – use of feeding protocols – small bowel feeding • Minimize interruptions, make up volume • Other enteral formulas with supplmental glutamine, vitamins, minerals not allowed – No supplements with high amounts of Zinc • Renal Dysfunction – Switch to lower protein formula – Restrict fluid – Refer to appendix Pilot study: Interruptions due to high urea only in 2% patient days (9% patients) If received volumes < Prescribed = Protocol Violation……….notify Methods Centre !! Screening and Randomization Web Login Page Welcome Home Page (Site Status Page) Patient Status Page Inclusion/exclusion criteria Refer to inclusion/exclusion criteria cards Inclusion Criteria Exclusion Criteria CORRECTION: should be >24 hours from ICU admission to time of consent Randomization Refer to Appendix 1 Randomization on Web Screen New Subject “Only Subjects Who Meet Inclusion Criteria” Screening Form Inclusion/Exclusion No Exclusion Eligible for Study Pre Randomization Form Eligibility Must Be Confirmed By MD Do you obtain consent? Yes Consent Obtained Subject’s Height in cm. CLICK here to Randomize Patient button Subject is now Randomized Enrollment Number Is____ Contact your Site Pharmacy and enter date and time of contact. Provide Height/Subject Initials/ DOB/Enrollment Number Meets an Exclusion End s End Pharmacist Receives call from Study Coordinator Explain why No Pharmacist Logs onto Web Pharmacist Receives Treatment Assignment Subject’s Initials Date of Birth Height After Randomization Study Coordinator Expected to Complete Baseline Form & APACHE Score and other Electronic CRFs Pre-Randomization Consent If Randomized Print the page and notify the study pharmacist of: • Patient randomization number • Height in cms • Patient initials and DOB Consent Enter Screening Data for ALL patients meeting inclusion criteria, including those meeting an exclusion criteria and those that END refuse consent! Pharmacy Pharmacy Log In Pharmacy Treatment assignment Note: this is not the randomization list that will be used for the study. Supply of Supplements • Fresenius Kabi and Baxter (Calea) • Before start: Supplies to be shipped to sites • Need updated pharmacy contact and shipping address Dispensing • ICU pharmacist dispensing pharmacist • Sign signature log • Enteral supplements – no mixing needed • Parenteral supplements – Mixing required: Dipeptiven (Glutamine) + Selenium (AOX) + Normal Saline Enteral Products • Obtain appropriate enteral product • Infuse at 20 ml/hour for all patients • Generate pharmacy label (need 2 labels) Remove company label and staple to Form B Attach pharmacy label to bottle (maintain blinding) Enteral Dispensing Log Mixing of Parenteral Supplements Dipeptiven (Glutamine) + Selenium (AOX) + Normal Saline Final volume = 250 mls, hourly rate = 10 ml/hr. 1. Determine dose of Glutamine according to Normal weight • Normal Weight (kg) = height (cms) –100 cms • Dose of Dipeptiven = Normal wt. X 2.5 mls (This equals to Normal wt. X 0.35 gms of Glutamine or Normal weight X 0.5 gms of L-alanyl-L-Glutamine). 2. Dose of Selenium = 12.5 ml (500 micrograms) = 1.25 vial 3. Combine the Glutamine + Selenium and remove this volume from 250 ml of normal saline. 4. Replace normal saline with this mixture. Final volume =250 mls. Parenteral Worksheet: AOX Should be 10.8 ml/hr Parenteral Worksheet: GLN Should be 10.8 ml/hr Parenteral Worksheet: AOX+GLN Should be 10.8 ml/hr Parenteral Worksheet: Placebo Should be 10.8 ml/hr Expiration of Supplements • Selenium once opened: 24 hrs if refrigerated • Dipeptiven once opened: mix immediately • Once mixed, parenteral solutions have an expiration of 96 hrs room temperature – Can make in batches to last 3 days!! Enteral Supplements once opened: 24 hrs Parenteral Study Supplement Log Parenteral Label Dosages according to height (PN) If > 6 feet 5 inches (>196 cms) •Final volume of parenteral solution will be between 250-300 mls. •Can still use 250 mls bag of saline •If no normal saline to be used, use an empty sterile bag and add supplements to the bag (instead of removing all normal saline) •Final rate of solution will exceed 10 ml/hr •Central line needed but peripheral may be used (72 hrs max) Pilot Study: no one > 190 cms (6’3”) Nutrient Accountability Logs One log for each product except for normal saline Monthly Site Inventory Log Fax in to CERU monthly Temperature Log Fax in to CERU monthly Study Coordinator General Rules for Data Collection • • • • • • CERU to assign passwords, site # Dates DD/MMM/YYYY, 00:00 Click on + to expand menu or taxonomy Site Status Page: shows all patients Patient Status Page : colour coding Input warnings : help with query process Site Status Page Patient Status Page Duration of Data Collection For daily data from Study Day 1 until Day 30 unless ICU discharge (actual) or death occurs before day 30 EXCEPT the following: – Study Supplement Compliance: maximum of 28 days. – Microbiology: -7 days ICU admission to ICU discharge. – Antibiotics: -7 days ICU admission and stop dates may extend beyond ICU discharge. – Patients with ICU stay < 5 days and transferred to ward: collect all daily data from Study Day 1 and continue for 5 days in total (=120 hrs). Study Day 1 is from ICU admission to end of flowsheet. Study Day 2 and subsequent days are according to your 24 hr flowsheet Baseline Hypotension Respiratory Failure OK to wait Must be completed Logical sequence APACHE II May use existing APACHE score if available Lowest and highest values Score automatically generated Study Supplement Timelines Duration of supplements: • Minimum 5 days (120 hrs) • Maximum 28 days Start and stop dates and times Baseline Nutrition Dietitian to collect: • Prescribed kcal and protein (baseline) • Type of nutrition support • Start and stop date and times • Refer to Dietitian Manual Daily Data Study Day 1 is from ICU admission to end of your 24 hr flowsheet. Study Day 2 and subsequent days are according to your 24 hr flowsheet. Dietitian may help by collecting the location of feeding tube Daily Nutrition • Dietitian to collect the data and give to SC • Close to real time to ensure that patient is being fed adequately. • Use checklist (see sample in Dietitian Manual) Dietitian Checklist Study Supplement Compliance • Volumes must be monitored DAILY in real time. • If volumes < prescribed, need to report to CERU or provide explanation and take action to prevent recurrence. Protocol Violation Protocol Deviation Protocol Violation Protocol Deviation Volume of study supplement actually received is less than the prescribed volume in 24hrs Volume of study supplement actually received is less than the prescribed volume in 24hrs Enteral < 80% prescribed Parenteral <90% prescribed Enteral ≥ 80% < 100% prescribed Parenteral ≥ 90% <100% prescribed Complete Violation Form within 24 hours of discovery & Fax to CERU Attention: Project Leader (613) 548-2428 Provide explanation on the worksheet/web based data entry (Study Supplement Compliance) Protocol Violation Form Vasopressors/Inotropes Highest hourly dose received Concomitant Medications Input Warnings Microbiology Collect all positive cultures starting 7 days prior to ICU admission. If culture date> 72 hrs ICU admission, 2 questions will be asked to help determine suspicion of ICU acquired infection. Suspicion of ICU Infection • Is this culture a manifestation of a previously diagnosed infection? • Is this a routine surveillance swab? NEED TO ASK SITE INVESTIGATOR • If NO to both………………..flag for adjudication (to be done after ICU outcomes). Antibiotics Period of data collection starts 7 days prior to ICU admission and may extend beyond ICU discharge. If abx started > 72 hr ICU admission, 3 questions will be asked to help determine suspicion of ICU acquired infection. Suspicion of ICU Infection • Is this antibiotic prescribed for prophylaxis? • Is this a dose adjustment for an antibiotic ordered for a previous infection? • Is this a substitute for an antibiotic ordered for a previous infection? NEED TO ASK SITE INVESTIGATOR • If NO to ALL………………..flag for adjudication (to be done after ICU outcomes). ICU Outcomes All input warnings must be addressed before you can access this page. The input warnings will appear at the top of the Patient Status Page. This page MUST be completed before you can proceed to the next web pages Infection Adjudication All input warnings must be resolved Automatic listing of relevant clinical data (microbiology. antibiotics, daily data) that will enable the Site Investigator to adjudicate newly acquired ICU infections. Determination of ICU Infection Was this culture or the prescription of this antibiotic for a NEW ICU acquired infection? (after 72 hours of admission from ICU admission)? Yes Choose the appropriate Categories of Infection (1-12)* and if: Definite Yes or Probable Yes or Possible Yes No NO, because it is related to an infection previously diagnosed and adjudicated. NO, because it is NOT an infection Possible** NO *Categories of Infection: Appendix 8.2 **Definition of No: Appendix 8.3 END Probable* * NO END Hospital Outcomes 3 and 6 month f/up SF-36 at 3 and 6 months Investigator’s Confirmation Only appears once the ICU and Hospital outcomes have been completed and all input warnings have been resolved (Patient Status Page). SAE Reporting • Serious and Unexpected events – regardless of relationships to supplements • Initial report faxed within 48 hrs • Final report at day 30, ICU d/c, death or 10 days from becoming aware of SAE • Record the event, not the outcome (death) SAE Initial Report SAE Follow up Report Daily Monitoring • Enteral Study Supplement Volumes < 80 % prescribed: Protocol Violation Form >= 80 and < 100 %: Provide explanation • Parenteral Study Supplement Volumes < 90% prescribed: Protocol Violation Form >=90 and < 100%: provide explanation • SAEs: unexpected: report within 48 hrs, 10 days • Start of antibiotics > 72 hrs ICU admit, ask SI • Positive Cultures > 72 hrs ICU admit: ask SI Threats to Success • • • • Poor enrollment, competing studies. Inadequate delivery of study supplements. Inadequate delivery of enteral nutrition. Additional training needs? Questions?